Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

References for PMC Articles for PubMed (Select 20507622)

1.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR.

Clin Infect Dis. 2010 Jan 1;50(1):98-105. doi: 10.1086/648729.

2.

Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care.

Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, Johnson EN, Ordóñez CE, Wortmann GW, Marconi VC; IDCRP HIV Working Group.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):574-80. doi: 10.1097/QAI.0b013e3181b98537.

PMID:
19755913
3.

Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco.

Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR.

J Gen Intern Med. 2009 Jan;24(1):14-20. doi: 10.1007/s11606-008-0824-5. Epub 2008 Oct 25.

4.

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.

5.

Estimation of HIV incidence in the United States.

Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS; HIV Incidence Surveillance Group.

JAMA. 2008 Aug 6;300(5):520-9. doi: 10.1001/jama.300.5.520.

6.

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries.

Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, Schechter M, Laurent C, Keiser O, May M, Sprinz E, Egger M, Anglaret X; ART-LINC, IeDEA.

Bull World Health Organ. 2008 Jul;86(7):559-67.

7.

Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART.

Weintrob AC, Fieberg AM, Agan BK, Ganesan A, Crum-Cianflone NF, Marconi VC, Roediger M, Fraser SL, Wegner SA, Wortmann GW.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):40-7. doi: 10.1097/QAI.0b013e31817bec05.

PMID:
18667932
8.
9.

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.

Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Weber R; Swiss HIV Cohort Study.

J Infect Dis. 2008 Jun 15;197(12):1685-94. doi: 10.1086/588141.

10.

CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ.

Nat Med. 2008 Apr;14(4):413-20. doi: 10.1038/nm1741. Epub 2008 Mar 30.

11.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
12.

Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting.

Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, Wood E, Montaner JS, Hogg RS.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):500-5. doi: 10.1097/QAI.0b013e3181648dfd.

PMID:
18197117
13.

The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy.

Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):194-201.

PMID:
17971712
14.

Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.

Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M.

J Antimicrob Chemother. 2007 Oct;60(4):724-32. Epub 2007 Aug 21. Review.

15.

Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.

Tyndall MW, McNally M, Lai C, Zhang R, Wood E, Kerr T, Montaner JG.

Int J Drug Policy. 2007 Aug;18(4):281-7. Epub 2006 Dec 27.

PMID:
17689376
16.
17.
18.

The association of antidepressant medication adherence with employee disability absences.

Burton WN, Chen CY, Conti DJ, Schultz AB, Edington DW.

Am J Manag Care. 2007 Feb;13(2):105-12.

19.

Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.

Hessol NA, Kalinowski A, Benning L, Mullen J, Young M, Palella F, Anastos K, Detels R, Cohen MH.

Clin Infect Dis. 2007 Jan 15;44(2):287-94. Epub 2006 Dec 12.

20.

Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001.

Hall HI, McDavid K, Ling Q, Sloggett A.

Ann Epidemiol. 2006 Nov;16(11):824-33. Epub 2006 Oct 24. Erratum in: Ann Epidemiol. 2007 Aug;17(8):642.

PMID:
17067817
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk